Who will have the best response to entecavir?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 1, 2013, Pages 5-7

  Wong, Grace Lai Hung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON; TENOFOVIR DISOPROXIL; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; EDITORIAL; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84871650559     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12009     Document Type: Editorial

References (19)

1. Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin. Liver Dis. 2006; 26: 153-161.
2. European Association for the Study of the L. EASL Clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167-185.
3. Liaw YF, Kao JH, Piratvisuth T etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol. Int. 2012; 6: 531-561.
4. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
5. Wong GL, Chan HL. Predictors of treatment response in chronic hepatitis B. Drugs 2009; 69: 2167-2177.
6. Chan HL, Jia J. Chronic hepatitis B in Asia-new insights from the past decade. J. Gastroenterol. Hepatol. 2011; 26 (Suppl. 1): 131-137.
7. Chang TT, Lai CL, Kew YS etal. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430.
8. Wong GL, Wong VW, Chan HY etal. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment. Pharmacol. Ther. 2012; 35: 1326-1335.
9. Chang TT, Gish RG, de Man R etal. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1001-1010.
10. Wang CC, Tseng KC, Peng CY etal. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir. J. Gastroenterol. Hepatol. 2013; 28: 46-50.
11. Lau GK, Piratvisuth T, Luo KX etal. Peginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005; 352: 2682-2695.
12. Lok AS, Wu PC, Lai CL etal. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-2097.
13. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999; 30: 770-774.
14. Wong VW, Wong GL, Tsang SW etal. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Antivir. Ther. 2008; 13: 571-579.
15. Chang TT, Liaw YF, Wu SS etal. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893.
16. Wong VW, Chan HL. Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease. J. Gastroenterol. Hepatol. 2009; 24: 1179-1186.
17. Wong VW, Wong GL, Yiu KK etal. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J. Hepatol. 2011; 54: 236-242.
18. Lok AS, Trinh H, Carosi G etal. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology 2012; 143: 619-628.
19. Zoutendijk R, Reijnders JG, Zoulim F etal. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2012. doi:10.1136/gutjnl-2012-302024. [Epub ahead of print].